Literature DB >> 21532972

How do prescription opioid users differ from users of heroin or other drugs in psychopathology: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Li-Tzy Wu1, George E Woody, Chongming Yang, Dan G Blazer.   

Abstract

OBJECTIVES: To study substance use and psychiatric disorders among prescription opioid users, heroin users, and non-opioid drug users in a national sample of adults.
METHODS: Analyses of data from the 2001-2002 National Epidemiologic Survey on Alcohol and Related Conditions (N=43,093).
RESULTS: Four groups were identified among 9140 illicit or non-prescribed drug users: heroin-other opioid users (1.0%; used heroin and other opioids), other opioid-only users (19.8%; used other opioids but never heroin), heroin-only users (0.5%; used heroin but never other opioids), and non-opioid drug users (78.7%; used drugs but never heroin or other opioids). After adjusting for variations in socioeconomic characteristics, history of substance abuse treatment, and familial substance abuse, heroin-other opioid users had greater odds of several substance use disorders (cocaine, hallucinogen, sedative, amphetamine, and tranquilizer) as compared with the other groups; heroin-only users had reduced odds of sedative and tranquilizer use disorders as compared with other opioid-only users. Non-opioid drug users had reduced odds of all substance use disorders and other mental disorders (mood, anxiety, pathological gambling, and personality) as compared with other opioid-only users. Past-year other opioid-only users also reported slightly lower scores on quality of life than past-year non-opioid drug users.
CONCLUSIONS: All opioid use groups had higher rates of substance use disorders than non-opioid drug users, and these rates were particularly elevated among heroin-other opioid users. Findings suggest the need to distinguish between these four groups in research and treatment as they may have different natural histories and treatment needs.

Entities:  

Keywords:  Comorbidity; Heroin use disorders; Opioid use disorders; Prescription opioid abuse

Mesh:

Substances:

Year:  2011        PMID: 21532972      PMCID: PMC3082206          DOI: 10.1097/ADM.0b013e3181e0364e

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  18 in total

1.  Illicit opioid use in the 21st century: witnessing a paradigm shift?

Authors:  Benedikt Fischer; Jurgen Rehm
Journal:  Addiction       Date:  2007-04       Impact factor: 6.526

2.  Co-morbid pain and psychopathology in males and females admitted to treatment for opioid analgesic abuse.

Authors:  Theodore J Cicero; Michael Lynskey; Alexandre Todorov; James A Inciardi; Hilary L Surratt
Journal:  Pain       Date:  2008-05-01       Impact factor: 6.961

Review 3.  The self-medication hypothesis of substance use disorders: a reconsideration and recent applications.

Authors:  E J Khantzian
Journal:  Harv Rev Psychiatry       Date:  1997 Jan-Feb       Impact factor: 3.732

4.  Prescription opioid abuse among enrollees into methadone maintenance treatment.

Authors:  Andrew Rosenblum; Mark Parrino; Sidney H Schnoll; Chunki Fong; Carleen Maxwell; Charles M Cleland; Stephen Magura; J David Haddox
Journal:  Drug Alcohol Depend       Date:  2007-03-26       Impact factor: 4.492

5.  Increasing deaths from opioid analgesics in the United States.

Authors:  Leonard J Paulozzi; Daniel S Budnitz; Yongli Xi
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-09       Impact factor: 2.890

6.  Substance use disorders among inhalant users: results from the National Epidemiologic Survey on alcohol and related conditions.

Authors:  Li-Tzy Wu; Matthew Owen Howard; Daniel J Pilowsky
Journal:  Addict Behav       Date:  2008-03-10       Impact factor: 3.913

7.  Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities.

Authors:  M T Tsuang; M J Lyons; J M Meyer; T Doyle; S A Eisen; J Goldberg; W True; N Lin; R Toomey; L Eaves
Journal:  Arch Gen Psychiatry       Date:  1998-11

8.  Gender and non-medical use of prescription opioids: results from a national US survey.

Authors:  Jeanette M Tetrault; Rani A Desai; William C Becker; David A Fiellin; John Concato; Lynn E Sullivan
Journal:  Addiction       Date:  2007-11-27       Impact factor: 6.526

Review 9.  National drug control policy and prescription drug abuse: facts and fallacies.

Authors:  Laxmaiah Manchikanti
Journal:  Pain Physician       Date:  2007-05       Impact factor: 4.965

10.  Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients.

Authors:  Brent A Moore; David A Fiellin; Declan T Barry; Lynn E Sullivan; Marek C Chawarski; Patrick G O'Connor; Richard S Schottenfeld
Journal:  J Gen Intern Med       Date:  2007-04       Impact factor: 5.128

View more
  47 in total

1.  Advances in opioid antagonist treatment for opioid addiction.

Authors:  Walter Ling; Larissa Mooney; Li-Tzy Wu
Journal:  Psychiatr Clin North Am       Date:  2012-04-10

2.  Buprenorphine Initiation and Linkage to Outpatient Buprenorphine do not Reduce Frequency of Injection Opiate Use Following Hospitalization.

Authors:  Phoebe A Cushman; Jane M Liebschutz; Bradley J Anderson; Merredith R Moreau; Michael D Stein
Journal:  J Subst Abuse Treat       Date:  2016-06-11

3.  Buprenorphine for prescription opioid addiction in a patient with depression and alcohol dependence.

Authors:  Marc J Fishman; Li-Tzy Wu; George E Woody
Journal:  Am J Psychiatry       Date:  2011-07       Impact factor: 18.112

4.  Spontaneous reductions in smoking during double-blind buprenorphine detoxification.

Authors:  Mollie E Patrick; Kelly E Dunn; Gary J Badger; Sarah H Heil; Stephen T Higgins; Stacey C Sigmon
Journal:  Addict Behav       Date:  2014-05-05       Impact factor: 3.913

5.  Perceived health, medical, and psychiatric conditions in individual and dual-use of marijuana and nonprescription opioids.

Authors:  Tessa Frohe; Cheryl L Beseler; Andres M Mendoza; Linda B Cottler; Robert F Leeman
Journal:  J Consult Clin Psychol       Date:  2019-10

Review 6.  Achieving Smoking Cessation Among Persons with Opioid Use Disorder.

Authors:  Cynthia Vlad; Julia H Arnsten; Shadi Nahvi
Journal:  CNS Drugs       Date:  2020-04       Impact factor: 5.749

7.  Baseline characteristics and treatment outcomes in prescription opioid dependent patients with and without co-occurring psychiatric disorder.

Authors:  Margaret L Griffin; Dorian R Dodd; Jennifer S Potter; Lindsay S Rice; William Dickinson; Steven Sparenborg; Roger D Weiss
Journal:  Am J Drug Alcohol Abuse       Date:  2013-11-12       Impact factor: 3.829

8.  Lifetime history of heroin use is associated with greater drug severity among prescription opioid abusers.

Authors:  Andrew C Meyer; Mollie E Miller; Stacey C Sigmon
Journal:  Addict Behav       Date:  2014-11-18       Impact factor: 3.913

9.  Co-occurring prescription opioid use problems and posttraumatic stress disorder symptom severity.

Authors:  Andrea Meier; Chantal Lambert-Harris; Mark P McGovern; Haiyi Xie; Melissa An; Bethany McLeman
Journal:  Am J Drug Alcohol Abuse       Date:  2014-05-08       Impact factor: 3.829

10.  Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens.

Authors:  Marco Pravetoni; Morgan Le Naour; Ashli M Tucker; Theresa M Harmon; Tara M Hawley; Philip S Portoghese; Paul R Pentel
Journal:  J Med Chem       Date:  2013-01-15       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.